Exploring the Promising Weight Loss Drug Retatrutide
We’re gaining more insight into retatrutide, a highly effective weight loss medication also known as “triple-G.” This drug uniquely targets three different metabolic receptors—GLP-1, GIP, and glucagon. As it approaches the final stages of clinical trials, it’s anticipated that the manufacturer, Eli Lilly, will seek FDA approval early next year.
There’s already significant interest surrounding retatrutide. The market for unapproved versions has surged, attracting attention from various groups—ranging from moms experiencing menopause to teens looking to enhance their appearance. In light of this, Eli Lilly is actively addressing the influx of knockoffs through a series of legal actions.
Recent data on its effectiveness is likely to intensify this excitement.
Earlier this year, Eli Lilly shared the findings from its Phase 3 “Triumph-4” trial, revealing that participants lost, on average, 28.7% of their body weight. Interestingly, the dropout rates were notably higher in this trial; some individuals left because they had shed too much weight.
Now, they’ve released detailed results from another Phase 3 trial revealing that even at the lowest administered dose, participants experienced remarkable outcomes. Those who received a 4-mg injection weekly—the minimal dosage—lost an average of 29.8 pounds, translating to 12.7% of their body weight.
Details on Retatrutide’s Efficacy
Unlike GLP-1 medications like Ozempic, which focus solely on GLP-1 receptors, and dual agonists such as Mounjaro or Zepbound that target GLP-1 and GIP or glucagon, retatrutide engages all three receptors. Eli Lilly has shared data from three different dosages: 4 mg, 9 mg, and 12 mg.
After an 80-week period on the drug, participants who took the lowest dose lost an average of 29.8 pounds (12.7% of body weight), while those on the mid-range dosage lost 45.4 pounds (19.1%), and the highest dosage group lost 49.6 pounds (20.8%).
Additionally, retatrutide shows promise in lowering A1C levels, a critical blood sugar marker, which could have positive implications for those managing diabetes.
Dr. Juan P. Frías, who led the research, pointed out that a significant number of individuals with type 2 diabetes also struggle with obesity, making it challenging to address both conditions simultaneously. He noted that retatrutide considerably decreased both weight and blood sugar levels, with more than half of the participants no longer classifying as obese and about 40% achieving normal A1C levels.
On the lowest dose, A1C levels dropped by an average of 1.4%, which reduced further with increased dosages.
The drug also showed benefits for cardiovascular health. Notably, the highest dosage led to significant decreases in triglycerides, cholesterol, and blood pressure—factors linked to a lower risk of heart disease and stroke. It also reduced waist circumference, a significant heart disease risk indicator, along with high-sensitivity C-reactive protein, a marker for potential future heart issues.
Potential Side Effects of Retatrutide
As with many drugs in the GLP-1 category, the most common side effects noted by Lilly include gastrointestinal issues like diarrhea, which affected 27.4% to 33.6% of participants, along with nausea, constipation, reduced appetite, and vomiting—listed from most to least prevalent. Generally, side effects were more frequently reported at higher doses.
Participants also experienced dyesthesia, a neurological condition that alters touch sensations, leading to feelings like burning or tingling. This affected 4.5% to 7.3% of those involved, with higher instances occurring at greater dosages.
Additionally, some participants developed urinary tract infections, which occurred in 3.8% to 8% of cases, particularly as dosages increased.
Researchers noted that these side effects were mostly mild to moderate and tended to resolve throughout the course of treatment.
